eFFECTOR Therapeutics, Inc.
EFTR
$0.0002
$0.000.00%
OTC PK
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -19.72% | -8.66% | -19.26% | -29.46% | 112.37% |
| Gross Profit | 19.72% | -1.66% | 7.11% | 0.55% | -112.37% |
| SG&A Expenses | 5.57% | -8.15% | -28.28% | 0.03% | -14.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.95% | -8.51% | -22.37% | -20.59% | 45.63% |
| Operating Income | 11.95% | 1.43% | 15.09% | 0.33% | -45.63% |
| Income Before Tax | 11.78% | 1.40% | 13.14% | -20.95% | -426.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.78% | 1.40% | 13.14% | -20.95% | -426.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.78% | 1.40% | 13.14% | -20.95% | -426.30% |
| EBIT | 11.95% | 1.43% | 15.09% | 0.33% | -45.63% |
| EBITDA | 11.99% | 1.47% | 15.21% | 0.63% | -45.32% |
| EPS Basic | 63.69% | 38.59% | 42.10% | -3.99% | -417.34% |
| Normalized Basic EPS | 63.69% | 38.59% | 42.55% | 12.30% | -26.68% |
| EPS Diluted | 63.69% | 38.59% | 42.10% | -2.87% | -440.61% |
| Normalized Diluted EPS | 63.69% | 38.59% | 42.55% | 12.30% | -34.54% |
| Average Basic Shares Outstanding | 142.95% | 60.56% | 50.02% | 16.32% | 2.82% |
| Average Diluted Shares Outstanding | 142.95% | 60.56% | 50.02% | 16.32% | -3.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |